These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 38184584)

  • 1. Altering phosphorylation in cancer through PP2A modifiers.
    Johnson H; Narayan S; Sharma AK
    Cancer Cell Int; 2024 Jan; 24(1):11. PubMed ID: 38184584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of PP2A by Sphingolipid Metabolism and Signaling.
    Oaks J; Ogretmen B
    Front Oncol; 2014; 4():388. PubMed ID: 25642418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.
    Grech G; Baldacchino S; Saliba C; Grixti MP; Gauci R; Petroni V; Fenech AG; Scerri C
    Tumour Biol; 2016 Sep; 37(9):11691-11700. PubMed ID: 27444275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
    Perrotti D; Neviani P
    Cancer Metastasis Rev; 2008 Jun; 27(2):159-68. PubMed ID: 18213449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new paradigm for regulation of protein phosphatase 2A function via Src and Fyn kinase-mediated tyrosine phosphorylation.
    Sontag JM; Schuhmacher D; Taleski G; Jordan A; Khan S; Hoffman A; Gomez RJ; Mazalouskas MD; Hanks SK; Spiller BW; Sontag E; Wadzinski BE
    J Biol Chem; 2022 Aug; 298(8):102248. PubMed ID: 35820485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer.
    Fowle H; Zhao Z; Graña X
    Adv Cancer Res; 2019; 144():55-93. PubMed ID: 31349904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of PP2A.
    O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
    Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PP2A: The Wolf in Sheep's Clothing?
    Kiely M; Kiely PA
    Cancers (Basel); 2015 Apr; 7(2):648-69. PubMed ID: 25867001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol suppresses phosphorylation of ERα serine 167 through upregulation of PP2A in breast cancer cells.
    Hayashi T; Hikichi M; Yukitake J; Harada N; Utsumi T
    Oncol Lett; 2017 Dec; 14(6):8060-8065. PubMed ID: 29344249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein phosphatase 2A dysfunction in Alzheimer's disease.
    Sontag JM; Sontag E
    Front Mol Neurosci; 2014; 7():16. PubMed ID: 24653673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased holoenzyme assembly of protein phosphatase 2A (PP2A): From cancer to small molecules.
    Haanen TJ; O'Connor CM; Narla G
    J Biol Chem; 2022 Dec; 298(12):102656. PubMed ID: 36328247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation and role of the PP2A-B56 holoenzyme family in cancer.
    Peris I; Romero-Murillo S; Vicente C; Narla G; Odero MD
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188953. PubMed ID: 37437699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase 2A is associated with class C L-type calcium channels (Cav1.2) and antagonizes channel phosphorylation by cAMP-dependent protein kinase.
    Davare MA; Horne MC; Hell JW
    J Biol Chem; 2000 Dec; 275(50):39710-7. PubMed ID: 10984483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer.
    Thompson JJ; Williams CS
    Genes (Basel); 2018 Feb; 9(3):. PubMed ID: 29495399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.
    Yu H; Zaveri S; Sattar Z; Schaible M; Perez Gandara B; Uddin A; McGarvey LR; Ohlmeyer M; Geraghty P
    Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
    Kauko O; O'Connor CM; Kulesskiy E; Sangodkar J; Aakula A; Izadmehr S; Yetukuri L; Yadav B; Padzik A; Laajala TD; Haapaniemi P; Momeny M; Varila T; Ohlmeyer M; Aittokallio T; Wennerberg K; Narla G; Westermarck J
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein phosphatase 2A in the healthy and failing heart: New insights and therapeutic opportunities.
    Sergienko NM; Donner DG; Delbridge LMD; McMullen JR; Weeks KL
    Cell Signal; 2022 Mar; 91():110213. PubMed ID: 34902541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the complexity: A comprehensive analysis of the PP2A in cancer and its potential for novel targeted therapies.
    Ivovič D; Kabelíková P; Jurkovičová D
    Neoplasma; 2023 Aug; 70(4):485-499. PubMed ID: 37789785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer.
    Kurimchak A; Graña X
    Genes Cancer; 2012 Nov; 3(11-12):739-48. PubMed ID: 23634261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.